共 14 条
[4]
Probucol therapy improves long-term (>10-year) survival after complete revascularization: A propensity analysis[J] . Takatoshi Kasai,Katsumi Miyauchi,Naozumi Kubota,Kan Kajimoto,Atsushi Amano,Hiroyuki Daida.Atherosclerosis . 2011 (2)
[5]
HDL Structure, Function, Therapeutics, and Imaging[J] . Stanley Hazen.Arteriosclerosis, Thrombosis, and Vascular Biology . 2010 (2)
[6]
Where are we with probucol: A new life for an old drug?[J] . Shizuya Yamashita,Yuji Matsuzawa.Atherosclerosis . 2009 (1)
[7]
Viability of developing CETP inhibitors
[J].
CARDIOVASCULAR THERAPEUTICS,
2008, 26 (02)
:135-146
[8]
Probucol markedly reduces HDL phospholipids and elevated preβ1-HDL without delayed conversion into α-migrating HDL: Putative role of angiopoietin-like protein 3 in probucol-induced HDL remodeling[J] . Takashi Miida,Utako Seino,Osamu Miyazaki,Osamu Hanyu,Satoshi Hirayama,Toshikazu Saito,Yuichi Ishikawa,Suguru Akamatsu,Toshimitsu Nakano,Katsuyuki Nakajima,Mitsuyo Okazaki,Masahiko Okada.Atherosclerosis . 2008 (2)
[10]
Baseline Disease Activity, Hyperlipidemia, and Hypertension Are Predictive Factors for Ischemic Stroke and Stroke Severity in Systemic Lupus Erythematosus[J] . Jamal Mikdashi,Barry Handwerger,Patricia Langenberg,Michael Miller,Steven Kittner.Stroke . 2007 (2)